FierceBiotechOriginal article
{"a":[{"_":"Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug","$":{"href":"/biotech/royalty-pharma-pens-425m-deal-slice-sales-astrazenecas-attr-drug","hreflang":"en"}}]}
PartnershipAstraZeneca ATTR drugPositive
AI Analysis
Summary
Royalty Pharma acquired a stake in AstraZeneca's ATTR drug through a $425 million deal with Neurimmune, paying $125 million upfront for a slice of future sales.
Importance:6/10
Sentiment:
0.60
royalty dealpartnershiptransthyretin amyloidosisAstraZenecaNeurimmune
Read the original article
Published by FierceBiotech on July 22, 2026 9:31 AM